68Ga-ICAM-1pep

68Ga-ICAM-1pep is a radiopharmaceutical imaging agent under early clinical investigation for use in positron emission tomography/computed tomography (PET/CT) imaging. It consists of a peptide ligand labeled with the radioisotope gallium-68 (68Ga), designed to target intercellular adhesion molecule 1 (ICAM-1), which is often overexpressed in various tumor types and associated with neoplasm metastasis. The primary mechanism involves specific binding to ICAM-1, enabling visualization and quantification of ICAM-1 expression in tumors via PET/CT scans. The drug is being developed primarily for assessing tumor responses to radiotherapy and potentially aiding diagnosis or staging of metastatic cancers[1][4][5]. Its development was initiated by Beijing Cancer Hospital.